Encision, Inc. · OTC:ECIA
Encision — 2014 LD Micro Investor Conference
10 slides from Encision's conference presentation, December 2014
Slide 1: Encision AEM Safety - Performance - Value
ENCISIGN AEM SAFETY - PERFORMANCE - VALUE ECIA
Slide 2: Encision Inc. Disclaimer Statement
Encision Inc. Disclaimer Statement The following information does not purport to be all-inclusive or to contain all the information that you may desire for investing in Encision. You should conduct and rely on your own evaluation of Encision, including the merits and risks involved, in making an inv
Slide 3: Strong Need for Encision's AEM Technology
Strong Need for Encision’s AEM® Technology • 4M Laparoscopic surgical procedures in the US in 2014. 75% use Monopolar Surgical Energy. • Stray Energy kills 400-600 patients each year in the United States and severely injures another 1800- 2000. (Fecal Peritonitis Post Operative Sepsis) • CMS is pena
Slide 4: Forms of Stray Energy in Laparoscopy
Forms of Stray Energy in Laparoscopy Insulation Failure Capacitive Coupling Active Electrosurgical Electrode Active Electrosurgical Electrode Insulation Failure: Between 400-600 Patients die 1 in 5 – Reusables each year from stray energy burns 1 in 33 – Disposables J Urol 1999 Mar;161(3):887-90 (SAG
Slide 5: AEM Value Positioning
AEM® Value Positioning Dangerous Stray Energy Clinical Value Proposition: AEM® Technology alone saves patient lives by eliminating stray energy burns during laparoscopy. Economic Value Proposition: AEM® Technology alone reduces hospital liability by eliminating a source of surgical complications and
Slide 6: Why Encision and AEM Now?
Why Encision and AEM® Now? • Increased Customer and Market Awareness • CMS HAC Reduction Initiative and Penalties • Strong Clinical Messaging & Evidence • Strong Economic Drivers • HAC Reduction • APL Reduction • Reduced Readmissions • Reduced Risk and Liability Conservative estimates over $600,000,
Slide 7: Encision 2014 – Rebuilding to Win
Encision 2014 – Rebuilding to Win Sales New Product Introduction Medical Conferences Advertising Awareness & Demand HCP Education Programs Creation 12 Sellers 50 Sellers Create, Train, and Equip US Sales Channel It’s not the surgical technique – It’s a fundamental flaw in the energy Repositioning
Slide 8: Financial Metrics at Sep 30, 2014 (2nd fq)
Financial Metrics at Sep 30, 2014 (2nd fq) • Revenue (ttm) $9.7M • Net loss (ttm) (excluding $1.1M impairment) $0.9M • Cash $1.0M • Borrowings None, with $0.8M availability • Stockholders’ Equity $4.0M • Shares Outstanding 10.7M
Slide 9: Encision Vision
Encision Vision 20% Annual Growth Objective • New AEM® Product Development • US & OUS Channel Expansion • Increased Customer Awareness • New CMS Reimbursement Policies
Slide 10: Take Aways:
Take Aways: • It’s our time! • We have set Encision up to win Solid clinical and economic positioning Growing awareness and sales pipeline Favorable tailwinds from CMS Initiative • Poised to inflect sales and drive shareholder value • Interested? Please reach out to us! Gregory Trudel, Preside